Hoffmann-La Roche

GO41854 (Skyscraper 03)

NCT04513925

JCP090

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

Status:

Recruiting

26459-200.png

III

Phase

Line of Therapy.png

2nd

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

PD-1, PD-L1, EGFR

Investigational

Product

Tiragolumab

anti-TIGIT antibody (i.v.)

Treatment Arms

o Experimental: Atezolizumab + Tiragolumab

o Active Comparator: Durvalumab